CIGNA Co. (NYSE:CI) Director William D. Zollars sold 212 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $205.68, for a total value of $43,604.16. Following the completion of the transaction, the director now owns 13,500 shares of the company’s stock, valued at $2,776,680. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of CIGNA Co. (CI) opened at $213.39 on Monday. The company has a market capitalization of $52,610.00, a P/E ratio of 23.37, a PEG ratio of 1.43 and a beta of 0.51. CIGNA Co. has a 12-month low of $133.52 and a 12-month high of $213.73. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.39 and a quick ratio of 0.39.

CIGNA (NYSE:CI) last posted its quarterly earnings data on Thursday, November 2nd. The health services provider reported $2.83 EPS for the quarter, beating the Zacks’ consensus estimate of $2.36 by $0.47. The business had revenue of $10.38 billion during the quarter, compared to analysts’ expectations of $10.17 billion. CIGNA had a return on equity of 18.85% and a net margin of 5.74%. The business’s revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.94 earnings per share. sell-side analysts anticipate that CIGNA Co. will post 10.34 EPS for the current fiscal year.

Several research analysts have recently issued reports on CI shares. Piper Jaffray Companies restated a “buy” rating and issued a $191.00 price objective on shares of CIGNA in a research note on Sunday, September 17th. Zacks Investment Research upgraded CIGNA from a “hold” rating to a “buy” rating and set a $214.00 price target for the company in a research report on Monday, October 9th. Jefferies Group lifted their price target on CIGNA from $201.00 to $221.00 and gave the company a “buy” rating in a research report on Friday, October 13th. BMO Capital Markets initiated coverage on CIGNA in a research report on Monday, October 16th. They set a “market perform” rating and a $210.00 price target for the company. Finally, Credit Suisse Group initiated coverage on CIGNA in a research report on Thursday, November 2nd. They set an “outperform” rating and a $219.00 price target for the company. Three research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. CIGNA has an average rating of “Buy” and an average target price of $205.18.

Institutional investors have recently bought and sold shares of the company. Saratoga Research & Investment Management acquired a new stake in shares of CIGNA in the third quarter worth approximately $112,000. Riverhead Capital Management LLC boosted its stake in shares of CIGNA by 159.3% in the second quarter. Riverhead Capital Management LLC now owns 5,511 shares of the health services provider’s stock worth $923,000 after acquiring an additional 3,386 shares during the last quarter. Iguana Healthcare Management LLC boosted its stake in shares of CIGNA by 51.4% in the third quarter. Iguana Healthcare Management LLC now owns 26,500 shares of the health services provider’s stock worth $4,954,000 after acquiring an additional 9,000 shares during the last quarter. Norinchukin Bank The boosted its stake in shares of CIGNA by 6.4% in the second quarter. Norinchukin Bank The now owns 17,766 shares of the health services provider’s stock worth $2,974,000 after acquiring an additional 1,062 shares during the last quarter. Finally, Sectoral Asset Management Inc boosted its stake in shares of CIGNA by 194.1% in the third quarter. Sectoral Asset Management Inc now owns 45,615 shares of the health services provider’s stock worth $8,527,000 after acquiring an additional 30,105 shares during the last quarter. Institutional investors and hedge funds own 87.75% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/15/insider-selling-cigna-co-ci-director-sells-212-shares-of-stock.html.

About CIGNA

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Insider Buying and Selling by Quarter for CIGNA (NYSE:CI)

Receive News & Stock Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related stocks with our FREE daily email newsletter.